Document:

exv10w2

 

EXHIBIT 10.2

International

Employee Stock

Purchase Plan

LSI LOGIC CORPORATION

Plan Document

Revision Date: February 2004

 

 

This International Employee Stock Purchase Plan must be read together with
the Country Addendum for the country in which you are employed. Where terms of
the Country Addendum are inconsistent with those stated in this document, the
terms of the Country Addendum shall govern.

-i- 

 

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page

	Introduction
	 	 	1	 
	Eligibility
	 	 	2	 
	Who May Participate
	 	 	2	 
	Enrollment
	 	 	3	 
	Enrolling in the IESPP
	 	 	3	 
	How the Plan Works
	 	 	4	 
	Offering Period/Purchase Period
	 	 	4	 
	Purchase Date/Purchase Price
	 	 	4	 
	Determination of Fair Market Value
	 	 	5	 
	Examples
	 	 	5	 
	Automatic Re-Enrollment in Subsequent Offering Period
	 	 	6	 
	Automatic Early Transfer to a New Offering Period
	 	 	6	 
	Payroll Deductions
	 	 	7	 
	Confirm IESPP Changes and Enrollment
	 	 	7	 
	Exchange Rate
	 	 	8	 
	Limitations on Shares You May Purchase
	 	 	8	 
	Use of Excess Funds
	 	 	9	 
	Changing Your Contribution Level
	 	 	9	 
	E*TRADE OptionsLink Account
	 	 	9	 
	Activating Your E*TRADE OptionsLink and E*TRADE Brokerage Account
	 	 	9	 
	Deposit of Shares
	 	 	10	 
	Sale of Shares
	 	 	10	 
	Account Records
	 	 	11	 
	Report of Sales to LSI Logic
	 	 	11	 
	Employee Stock Purchase Transmittals
	 	 	11	 
	Withdrawing from the IESPP
	 	 	11	 
	Termination of Plan Participation/Participation While on a Leave of Absence
	 	 	12	 
	Designating Your Beneficiary
	 	 	12	 
	Nonassignability
	 	 	13	 
	Administration of the IESPP
	 	 	13	 
	Amendment and Termination of the IESPP
	 	 	13	 
	Capital Changes
	 	 	14	 
	Conditions upon Issuance of Company Common Stock
	 	 	14	 
	Designation of Employer Subsidiaries and Country Addendum
	 	 	14	 
	Third Party Fiduciaries
	 	 	15	 
	Notices
	 	 	15	 
	Tax Consequences
	 	 	16	 
	Tax Implications of Purchasing and Selling Your Company Common Stock
	 	 	16	 
	Withholding and Employee-Paid Social Insurance
	 	 	16	 
	Other Information
	 	 	17	 
	Obtaining Additional Information
	 	 	17	 

-ii- 

 

Introduction

The Board of Directors of LSI Logic Corporation (the “Company”) has adopted the
International Employee Stock Purchase Plan (the “IESPP”) in order to provide
employees of designated LSI Logic subsidiaries with the opportunity to purchase
common stock of the Company at a below current market price through convenient
payroll deductions. If you decide to participate in the Plan, you can set aside
from 1% to 15% of your eligible compensation which will then be used to
purchase stock for you twice a year. Participation in the IESPP is voluntary.

As used in this IESPP, “Company Board” means the Board of Directors of the LSI
Logic Corporation. “Employer Subsidiary” means those subsidiaries of the
Company that have been designated by the Company as participants in the IESPP.
For more information about the Plan or its administration, you may contact the
LSI Logic Corporation Stock Administration Department, Mail Stop D-206, 1621
Barber Lane, Milpitas CA 95035, 1-408-433-6810.

IMPORTANT NOTE:

An effort has been made to have the terms of the IESPP apply to all IESPP
participants regardless of the country in which the participant is employed.
Notwithstanding that effort, certain different or additional terms may apply
for the IESPP as it applies to the country in which you are employed to
accommodate local requirements. Those terms are set forth in the Country
Addendum. Therefore, this document must be read together with the Country
Addendum that applies to your Employer Subsidiary. Where terms of your Country
Addendum are different from those stated in this document, the terms of the
Country Addendum shall apply.

This IESPP, together with the Country Addendum, if any, constitute part of a
prospectus covering securities that have been registered in the United States
under the Securities Act of 1933.

-1-

 

Eligibility

Who May Participate

You qualify to participate in the IESPP if all of the following are true:

	•	 	You are working as a regular employee of an Employer Subsidiary.
	 
	•	 	You are regularly scheduled by an Employer Subsidiary to work for
more than 20 hours per week and more than five months in each calendar
year.
	 
	•	 	You do not own five percent or more of the total combined voting
power or value of all classes of stock of the Company or of any
subsidiary of the Company, and

Temporary employees and independent contractors providing services to the
Company are not eligible to participate, regardless of the length of such
service.

Participation in the Plan does not create a contract for employment or limit in
any way the right of the Company to terminate the participant’s employment at
any time, with or without cause, or confer on a participant any right to
continue in the employ of the Company.

-2-

 

Enrollment

Enrolling in the IESPP

An eligible employee may become a participant in the IESPP by completing the
attached IESPP Subscription Agreement authorizing payroll deductions and
submitting it to your local Human Resource representative prior to an
Enrollment Date.

There are two Enrollment Dates each calendar year: May 15 and November 15.

Open enrollment is held during April and October before each Enrollment Date.

You must submit a completed IESPP Subscription Agreement during Open Enrollment
in order to participate as of the next Enrollment Date if:

	•	 	You are a new participant,
	 
	•	 	You are enrolling following a period of non-participation.

Your payroll deductions begin with the first payroll after the Enrollment Date.

New hires starting employment after the ESPP Open Enrollment Period and before
the beginning of the Offering Period can enroll up to and including the first
day of the Offering Period. The Subscription Agreement must be received no
later than the first day of the Offering Period.

If you miss the deadline for enrolling, you must wait until the next Open
Enrollment to enroll in the IESPP.

-3-

 

How the Plan Works

Offering Period/Purchase Period

An Offering Period lasts for 12 months unless you:

	•	 	withdraw
	 
	•	 	cease to be an Eligible Employee, or
	 
	•	 	are automatically transferred to a new Offering Period.

Each 12-month Offering Period consists of two consecutive Purchase Periods of
six months each. Offering Periods begin either on May 15 or November 15.

Purchase Date/Purchase Price

A Purchase Date is the last trading day of each Purchase Period within an
Offering Period. The Purchase Dates will be the last trading day on or before
May 14 or November 14.

On each Purchase Date your payroll deductions accumulated during the Purchase
Period are used to automatically purchase the maximum number of whole shares of
Company common stock that you are entitled to purchase under the IESPP.

The Purchase Price you will pay for the stock purchased under the IESPP is equal to the lower of:

	Þ	 	85% of the fair market value of the Company common stock on the Enrollment Date; or
	 
	Þ	 	85% of the fair market value of the Company common stock on the Purchase Date.

-4-

 

Determination of Fair Market Value

The fair market value of LSI Logic’s stock on a particular date is the closing
price of the stock on the New York Stock Exchange on that date in the United
States, as reported by the Wall Street Journal. However, if a closing price is
not available for a particular date, then the fair market value to be used for
that date will be the previous business day’s closing stock price. For
example, if the Enrollment date falls on a Saturday, the closing price of the
stock on the preceding Friday (or on the next preceding NYSE trading day, if
that Friday is not a business day) would be the fair market value on the
Enrollment Date.

Examples

The examples in this booklet are intended as illustrations only and are not
based on any actual or predicted value or performance of Company common stock.

Fair Market Value Higher on Purchase Date than on Enrollment Date

Let’s assume that the fair market value of Company common stock was US$8.00 per
share on the Enrollment Date. Assume that on a future Purchase Date in the
Offering Period, the fair market value of the common stock had risen to
US$10.00 per share.

As illustrated below, your Purchase Price would be US$6.80:

The lower of:

  85% x US$8.00= US$6.80 or

85% x US$10.00= US$8.50

Your Purchase Price is US$6.80

Fair Market Value Lower on Purchase Date than on the Enrollment Date

Let’s assume that the fair market value of Company common stock was US$8.00 per
share on the Enrollment Date. Assume that six months later the fair market
value of the Company common stock had decreased and the closing price of the
stock on the New York Stock Exchange on the Purchase Date was US$7.00 per
share.

As illustrated below, your Purchase Price would be US$5.95.

The lower of:

    85% x US$8.00= US$6.80 or

85% x US$7.00= US$5.95

Your Purchase Price is US$5.95

-5-

 

Automatic Re-Enrollment in Subsequent Offering Period

A new Offering Period begins each May 15 and November 15; however, you may be
enrolled in only one Offering Period at a time. Once you have completed an
IESPP Subscription Agreement authorizing payroll deductions to initially enroll
in the IESPP, you will be re-enrolled automatically as a participant in future
Offering Periods when an Offering Period in which you are currently enrolled
ends UNLESS:

	•	 	You withdraw from participation
	 
	•	 	Your employment terminates
	 
	•	 	You become otherwise ineligible to participate in the IESPP, or your
participation has terminated for any other reason
	 
	•	 	Your Employer Subsidiary withdraws from the IESPP
	 
	•	 	The IESPP terminates

Automatic Early Transfer to a New Offering Period

If the fair market value of the Company common stock is lower on a Purchase
Date than it was on the Enrollment Date, you are automatically withdrawn from
that Offering Period immediately after you purchase shares on such Purchase
Date and automatically re-enrolled in the next Offering Period. The effect of
this is to automatically begin a new 12-month Offering Period.

For example, in the second example described above, the fair market value on
the Enrollment Date was US$8.00, but had declined to US$7.00 on the Purchase
Date. Regardless of where you are in the current 12-month Offering Period, you
would be automatically withdrawn from that Offering Period following your
purchase of shares and re-enrolled in the next Offering Period.

Your payroll deductions will continue at the same rate during the new Offering
Period as in the prior Offering Period unless you instruct your local Human
Resource representative otherwise by submitting an ESPP Change Form within the
deadlines.

-6-

 

Payroll Deductions

You may contribute from 1% to 15% of your eligible compensation to the IESPP.
The percentage you deduct must be expressed in whole numbers. For purposes of
the IESPP, your eligible compensation includes all regular and recurring
straight time earnings, payments for overtime, shift premium, incentive
compensation, incentive payments, bonuses, commissions, but exclusive of other
compensation. Unless otherwise expressly provided in your Company Addendum,
eligible compensation excludes:

	•	 	car allowances
	 
	•	 	transportation allowances
	 
	•	 	housing allowances
	 
	•	 	dependent allowances
	 
	•	 	one-time incentive payments
	 
	•	 	one-time recognition awards (dinner for two, bravo & winners circle awards, and cash substitute)
	 
	•	 	disability pay (other than short-term salary continuation)
	 
	•	 	other compensation

Unless otherwise required under the laws of your country, all payroll
deductions contributed by IESPP participants will be held by the Company or the
Employer Subsidiary’s in its general fund until such time as the stock is
purchased. In order for payroll deductions to be applied to a particular
purchase date, they must be from a payroll date that is more than three
business days before that purchase date. Also, once payroll deductions are
taken, there are no restrictions on the Company’s or Employer Subsidiary’s use
of such accumulated payroll deductions.

Stock deductions calculated on retroactive pay adjustments, will be included in
the purchase period when the retroactive adjustment is paid.

Confirm IESPP Changes and Enrollment

It is your responsibility to review your first paycheck after the effective
date of change or an initial enrollment to make sure your instructions were
carried out.

If you have a problem with any IESPP change or enrollment you must notify Stock
Administration no later than 45 days from the beginning of the Offering Period
and provide your original fax confirmation from your requested change or
enrollment. For the November 15th Offering Period, the last day to notify
Stock Administration of any IESPP change or enrollment problems is December
31st. For the May 15th Offering Period, the last day to notify Stock
Administration of any IESPP change or enrollment problems is June 30th.

-7-

 

Exchange Rate

The exchange rate used for calculating the number of shares of stock to be
purchased with your payroll deductions is the NYSE Composite exchange rate
reported by Bloomberg Financial System using the closing rate on the last
Wednesday of the fiscal month ending closest to the Purchase Date.

Limitations on Shares You May Purchase

On each Enrollment Date of each Offering Period, each eligible Employee
participating in such Offering Period shall be granted an option to purchase on
each Exercise Date during such Offering Period (at the applicable Purchase
Price) up to a number of full shares of the Company’s Common Stock determined
by dividing such Employee’s payroll deductions accumulated prior to such
Exercise Date and retained in the Employee’s account as of the Exercise Date by
the applicable Purchase Price; provided that in no event shall an Employee be
permitted to purchase more than 1,000 shares in each Purchase Period within
Offering Periods commencing in the year 2003, provided further that such
purchase shall be subject to the limitations set forth below. The Board may,
for future Offering Periods, increase or decrease, in its absolute discretion,
the maximum number of shares of the Company’s Common Stock an Employee may
purchase during each Purchase Period of such Offering Period.

No employee will be permitted to purchase shares under the IESPP, if,
immediately after enrollment, the employee would own five percent or more of
the total combined voting stock of LSI Logic or of any subsidiary of LSI Logic
(including stock which may be purchased through the IESPP or pursuant to stock
options).

No employee will be permitted to purchase shares under the IESPP or any other
employee stock purchase plans of LSI Logic or its subsidiaries having a value
of more than $25,000 (determined using the fair market value of the shares on
such employee’s Enrollment Date) in any calendar year. This means that your
annual payroll contributions cannot exceed US$21,250.

The Company Board initially reserved 300,000 shares of Company common stock for
purchase by all participants under the IESPP, then increased that amount by an
additional 300,000 shares in March 1999, those shares were adjusted for the
stock split in February 2000, then increased that amount by an additional
1,000,000 in August 2000, an additional 27,273 in Jan 2001, and an additional
1,000,000 in August 2002 for a total reserve of 3,227,273 shares. If the
total number of shares to be purchased on any Purchase Date exceeds the
remaining reserved shares then available under the IESPP, a pro rata allocation
of the available Company common stock will be made among the participants, and
the IESPP will terminate unless additional Company common stock are added to
the IESPP.

Additional limitations on the number of shares of Company common stock that an
employee may purchase apply for employees of certain Employer Subsidiaries.
Please refer to the applicable Country Addendum.

-8-

 

Use of Excess Funds

Any contributions remaining in your account after the purchase has been made
for the current Purchase Date that are not sufficient to purchase a full share,
or exceed the amount required to purchase 1,000 shares, or exceed the $25,000
cap described above, will be refunded to you following the purchase of shares.

Changing Your Contribution Level

Once you are enrolled in the IESPP, you may reduce your contributions to a
lower level (but not below 1% of your eligible compensation) at any time.
Reducing your contribution level does not change your Purchase Price. To
reduce your contribution level, complete an ESPP Change Form and submit to your
local Human Resource representative showing the change in contribution level.

You may also increase your contribution level to a maximum of 15%. Increases
in your contribution level are only effective as of the beginning of a Purchase
Period. Increasing your contribution level does not change your Purchase
Price. To increase your contribution level, submit an ESPP Change Form to your
local Human Resource representative at least two weeks before the next Purchase
Period begins showing the change in contribution level.

The ESPP Change Form is available on the Stock Administration web site under
Planet LSI.

E*TRADE OptionsLink Account

The E*TRADE OptionsLink account is used for both the option program and the
Employee Stock Purchase Plan. For new IESPP participants, the OptionsLink
accounts are opened approximately 2 months prior to the purchase as long as you
are a current participant. E*TRADE will mail a welcome package to your home
once they receive the new account information from LSI Logic. In order to trade
you will need to complete the activation form and the form W-8BEN included in
the package and return to E*TRADE. If you have not received a welcome package
and you would like to activate your account so you can begin trading, then you
can follow the instructions below.

Activating Your E*TRADE OptionsLink and E*TRADE Brokerage Account

In order to begin trading in your E*TRADE OptionsLink account, the account
activation form and Form W-8BEN must be completed and received by E*TRADE. The
activation form and Form W-8BEN are included in the welcome package, or you can
login to www.optionslink.com and download these forms, or activate online which
is much faster. If you need assistance activating your account, call E*TRADE’s
International Customer Service number at 1-650-599-0125 and press “0”, # to
reach an operator. When your OptionsLink account is opened, an E*TRADE
Brokerage Account is automatically opened with it. There is no fee to activate
the E*TRADE Brokerage Account. When you sell shares from your OptionsLink
account the proceeds are deposited into your brokerage account. Your E*TRADE
Brokerage Account has no minimum balance, your funds earn interest, and you
have free check-writing privileges with funds in that account.

-9-

 

Deposit of Shares

Shortly after the close of each Purchase Period, LSI Logic will deposit your
purchased shares into your E*TRADE OptionsLink Account. Once your shares have
been deposited to your account, you may sell them at any time.

Sale of Shares

After you have activated your E*TRADE OptionsLink Account, you can login to
your account at www.optionslink.com to sell your shares.

Or, call the Interactive Voice Response System at 1-650-599-0125 from outside
the U.S.

Each IESPP purchase with sellable shares is tracked individually. You choose
which IESPP shares you want to sell in your OptionsLink account. That sale will
then be reported to LSI for disposition tracking purposes. Such sales will be
subject to commission charges at competitive rates.

There are no brokerage account fees or inactivity fees for your E*TRADE
accounts. The schedule below applies to transactions for selling shares:

	 	 	 	 	 	 	 
	

	 	IESPP Sales
	 	$	19.95	 
	Additional Charges:	 	 	 	 
	

	 	Broker Assisted Sale
	 	$	35	 
	

	 	Check Via Mail
	 	$	5	 
	

	 	Check Via Federal Express
	 	$	20	 
	

	 	Wire Transfer
	 	$	25	 
	

	 	Hold proceeds in E*TRADE
	 	No Charge

These rates are effective March 2003 and are subject to change without notice.

Employees have the flexibility to determine when and how they receive proceeds
from a sale:

	•	 	Sweep the proceeds into your E*TRADE Brokerage account (this account
earns interest and has free check-writing capabilities)
	 
	•	 	Wire Transfer
	 
	•	 	Mail or Overnight a check

-10-

 

Account Records

E*TRADE will provide each employee with a brokerage account statement
summarizing your account activity as well as written trade confirmations on all
executed orders. If there has been activity in your account, you will receive
a statement monthly; otherwise you will receive one quarterly, provided there
are assets in the account.

Report of Sales to LSI Logic

E*TRADE will provide LSI Logic with monthly reporting for all IESPP sales. For
more information regarding tax consequences of sale of shares acquired under
the IESPP see the applicable Country Addendum.

Employee Stock Purchase Transmittals

Twice a year, following each Purchase Date, you will receive an Employee Stock
Purchase Transmittal, from the Stock Administration Department at LSI Logic
which will detail the number of Company common stock purchased for you on the
preceding Purchase Date, the price paid per share and any remaining cash
balance in your account. The remaining cash balance will be refunded to you
following the purchase of shares.

Withdrawing from the IESPP

You may withdraw from the IESPP at any time by submitting an ESPP Change Form
to your local Human Resource representative of your Employer Subsidiary no
later than 30 days prior to the Purchase Date. The ESPP Change Form is
available on the Stock Administration web site under Planet LSI. Your
accumulated funds will be returned to you without interest unless the laws of
your country require otherwise as soon as practicable after your notice of
withdrawal has been received and processed. After withdrawal, you may not
re-enroll in the same Offering Period, although you may enroll in future
Offering Periods by completing an IESPP Subscription Agreement and submitting
it to your local Human Resource representative during a later enrollment
period.

If you re-enroll after withdrawal, your Purchase Price is determined on the
Enrollment Date of the new Offering Period.

-11-

 

Termination of Plan Participation/Participation While on a Leave of Absence

Your eligibility to participate in an Offering Period under the IESPP is
dependent on your maintaining continuous status as a regular employee scheduled
to work at least 20 hours per week during the Offering Period. If the number
of hours you are scheduled to work drops below 20 hours per week, you will be
deemed to have withdrawn from the Plan.

However, generally you may continue to participate in the Plan during a leave
of absence which is approved by your Employer Subsidiary. Unless you receive
regular straight time earnings during a leave of absence you will not make
contributions to the IESPP during your leave. Contributions made to the IESPP
prior to an approved leave of absence will be used to purchase stock at the end
of the Purchase Period. Payroll deductions will resume at the time you return
to active status. If you wish to discontinue participation in the Plan you
must notify your local Human Resource representative as soon as you return to
active status.

If your employment with the Company or any of its subsidiaries terminates for
any reason prior to the last business day of the purchase period, then all
payroll deductions which you have contributed, but which have not yet been used
to purchase stock, will be returned to you without interest.

Notwithstanding the above, your transfer from one Employer Subsidiary to
another Employer Subsidiary or to the parent Company shall not alone be
considered a break in your continuous status as a regular employee. In the
event of such a transfer, however, your participation in the IESPP would be
subject to the Country Addendum applicable to your new Employer Subsidiary or
to the terms of the Company Employee Stock Purchase Plan if to the parent
Company.

Designating Your Beneficiary

You may designate one or more beneficiaries in your IESPP Subscription
Agreement to receive your unused payroll deductions in the event of your death,
which will be paid without interest, unless required by local law. You Per
Compensation Committee approval on 2/12/04, the reference to the beneficiary’s
ability to purchase shares remaining in deceased employee’s account was
deleted.may change your beneficiary at any time by submitting a revised IESPP
Subscription Agreement to your local Human Resource representative of your
Employer Subsidiary. If no living beneficiary is designated, payment of
contributions or delivery of the share certificate, as the case may be, will be
made to your estate.

Laws governing the disposition of decedent’s property vary widely from country
to country. It is highly recommended that you consult with your own
independent legal counsel to make certain that you have taken all necessary
steps to ensure that your desired disposition of undistributed Company common
stock and payroll deductions in the event of your death can be accomplished.

-12-

 

Nonassignability

Unless where otherwise required under local law, none of your rights or
accumulated payroll deductions under the IESPP may be pledged, assigned,
transferred or otherwise disposed of for any reason (other than by will or the
laws of descent and distribution). Any such attempt may be treated by the
Company as an election to withdraw from the IESPP.

Administration of the IESPP

The IESPP is currently administered by the Company Board. All questions of
interpretation or application of the IESPP are determined in the sole
discretion of the Company Board (or its duly authorized committee) and its
decisions are final and binding upon all participants. Members of the Board who
are eligible employees are permitted to participate in the Plan but may not
vote on any matter affecting the administration of the Plan. No member of the
Board who is eligible to participate in the Plan may be a member of the
committee appointed by the Board to administer the Plan. No charges for
administrative or other costs may be made against the payroll deductions of a
participant in the IESPP. Members of the Board of Directors receive no
additional compensation for their services in connection with the
administration of the IESPP.

Subject to such rules, procedures and instructions as may be adopted by the
Company Board, each participating Employer Subsidiary shall be responsible for
making all payroll deductions (including related withholding and social
insurance contributions) for its participating employees, for filing and
distributing all reports and disclosures that may be required under local law,
and for otherwise ensuring compliance with all applicable local laws relating
to administration of the IESPP.

Amendment and Termination of the IESPP

The Company Board may at any time amend or terminate the IESPP or any
particular Country Addendum, or withdraw an Employer Subsidiary from the IESPP,
except that such amendment or termination will not adversely affect your
participation in an Offering Period for which you are already enrolled. Without
regard to whether any participant rights may be considered to have been
“adversely affected,” the Company Board shall be entitled to change the
Offering Periods, limit the frequency and/or number of changes in the amount
withheld during an Offering Period, establish the exchange ratio applicable to
amounts withheld in a currency other than U.S. dollars, permit payroll
withholding in excess of the amount designated by a participant in order to
adjust for delays or mistakes in the processing of properly completed
withholding elections, establish reasonable waiting and adjustment periods
and/or accounting and crediting procedures to ensure that amounts applied
toward the purchase of Company common stock for each participant properly
correspond with amounts withheld from the participant’s compensation and
establish such other limitations or procedures as the Company Board determines
in its sole discretion advisable which are consistent with the IESPP.

-13-

 

Capital Changes

If the number of Company common stock outstanding is increased or decreased by
way of stock split, stock dividend or otherwise (but not including conversion
of any convertible debentures), appropriate adjustments will be made in the
number of shares subject to purchase under the IESPP and in the Purchase Price
per share.

In the event of the proposed dissolution or liquidation of the Company, the
Offering Period then in progress will terminate immediately prior to such
dissolution or liquidation unless otherwise provided by the Company Board. In
the event of the proposed sale of all or substantially all of the assets of the
Company or the merger of the Company with or into another corporation, each
participant’s rights under the IESPP will be assumed or an equivalent right
will be substituted by the successor corporation, unless the Company Board
determines, in its discretion, to accelerate the Purchase Date(s) for all
current participants.

The Company Board, may also make provisions for adjusting the number of shares
subject to the IESPP and the Purchase Price per share in the event the Company
effects one or more reorganizations, recapitalizations, right’s offerings or
other increases or reductions of shares of the Company’s outstanding common
stock.

Conditions upon Issuance of Company Common Stock

Company common stock shall not be issued to you under this IESPP unless the
exercise of your option to purchase such Company common stock and the issuance
and delivery of such Company common stock pursuant thereto shall comply with
all applicable provisions of law, domestic or foreign, including, without
limitation, the Securities Act of 1933, as amended, the Securities Exchange Act
of 1934, as amended, the rules and regulations promulgated thereunder, and the
requirements of any stock exchange upon which the Company common stock may then
be listed, and shall be further subject to the approval of counsel for the
Company with respect to such compliance.

Designation of Employer Subsidiaries and Country Addendum

The Company Board may designate any subsidiary of the Company as a
participating Employer Subsidiary in the IESPP. The Company Board may, in
addition, modify one or more provisions of the IESPP solely as it applies to
such Employer Subsidiary. The applicable modified Country Addendum shall be
attached to the copy of the IESPP distributed to the Eligible Employees of the
applicable Employer Subsidiary.

-14-

 

Third Party Fiduciaries

Certain countries may prohibit employees from directly owning Company common
stock purchased on their behalf under the IESPP. If local law so requires or
if the Company Board determines that distribution of proceeds could not be
accomplished without undue liability or expense to either the Company or your
Employer Subsidiary, your Employer Subsidiary may provide for maintenance of
the accounts with a third party fiduciary for your benefit. Please refer to
your applicable Country Addendum to determine whether such arrangements apply
to you.

Notices

Any notice or other communication from you to the Company in connection with
the IESPP shall be considered properly given only if and when it is received in
the form specified by the Company at the following location:

	 	 	 
	

	 	LSI Logic Corporation
	

	 	Stock Administration
	

	 	1621 Barber Lane
	

	 	Mail Stop D-206
	

	 	Milpitas, California 95035

Any notice or other communication from you to your Employer Subsidiary in
connection with the IESPP shall be considered properly given only if and when
it is received in the form specified by the Employer Subsidiary at the location
designated in the attached Country Addendum.

The Employer Subsidiary and the Company may at any time change such notice
addresses upon prior written notice to you.

-15-

 

Tax Consequences

Tax Implications of Purchasing and Selling Your Company Common Stock

The Country Addendum applicable to you provides a brief summary of general
rules regarding the tax consequences in the country in which you are employed.
The Country Addendum does not purport to be a complete description of all tax
implications of participation in the IESPP, nor does it purport to discuss the
income tax implications of the IESPP under the laws of each state, province,
district or local government in which you may reside or otherwise be subject to
tax.

Withholding and Employee-Paid Social Insurance

Certain countries treat as taxable compensation the excess of the fair market
value of the Company common stock on the Purchase Date over the Purchase Price.
Certain countries also treat as taxable gain some or all of the excess, if
any, of the sale price over the fair market value of the Company common stock
as of the Purchase Date. (See your applicable Country Addendum for more
information.)

Some of those countries also require that the Employer Subsidiary withhold and
remit sums on behalf of the employee in respect of income taxes and/or social
insurance contributions. Any income, social or other taxes imposed on you for
the income arising from your participation in this IESPP will be your
responsibility.

The means by which this tax is satisfied will require that you pay all sums to
the Employer Subsidiary upon the purchase of Company common stock under the
IESPP, regardless of when you sell all or a portion of the Company common
stock. The attached Country Addendum will describe the mechanism by which such
economic burden is passed to you.

You are strongly urged to consult your own tax advisor concerning the
application of the various tax laws that may apply to your particular
situation.

-16-

 

Other Information

Obtaining Additional Information

Upon written or oral request to the Company, you may obtain copies, without
charge, of any of the following documents, which are incorporated by reference:

	•	 	The Company’s Annual Report on Form 10-K for the most recent fiscal
year;
	 
	•	 	The Company’s definitive Proxy Statement for the Company’s most
recent Annual Meeting of Stockholders;
	 
	•	 	The Company’s Quarterly Report(s) on Form 10-Q for the quarter(s)
ended since the end of the Company’s most recent fiscal year;
	 
	•	 	The description of the Company common stock contained in the
Company’s Registration Statement on Form 8-A filed with the Securities
and Exchange Commission of August 29, 1989;
	 
	•	 	All documents filed by the Company pursuant to Sections 13, 14 and
15(d) of the Securities Exchange Act of 1934 after the date of the
Registration Statement under which securities described herein are
registered.

In addition, upon written or oral request to the Company, you may obtain a
copy, without charge, of the Company’s most recent Annual Report to
Stockholders.

Requests for any of the documents described above should be directed to:

	 	 	 
	

	 	LSI Logic Corporation
	

	 	Investor Relations
	

	 	1621 BarberLane.
	

	 	Mail Stop D-115
	

	 	Milpitas, California 95035
	

	 	Phone 01 408 433 6777

For further information concerning the IESPP, contact the LSI Logic Corporation
Stock Administration Department.

-17-<PAGE>

                                                                   EXHIBIT 10.16

          CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
         SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                               DATED 18 JULY 2003

                       CANCER RESEARCH TECHNOLOGY LIMITED

                                     - and -

                          ALNYLAM PHARMACEUTICALS, INC

                          =============================

                                LICENCE AGREEMENT

                          =============================

                                  CONFIDENTIAL

                       CANCER RESEARCH TECHNOLOGY LIMITED
                                 Sardinia House
                                 Sardinia Street
                                 London WC2A 3NL

<PAGE>

THIS LICENCE AGREEMENT is made as of the 18th day of July 2003

BETWEEN:

(1)      CANCER RESEARCH TECHNOLOGY LIMITED a company registered in England
         (registered number 1626049) whose registered office is at Sardinia
         House, Sardinia Street 61, London WC2A 3NL ("CRT"); and

(2)      ALNYLAM PHARMACEUTICALS INC a Delaware company whose principal place of
         business is at 790 Memorial Drive, Cambridge, MA 02139 United States of
         America ("Alnylam")

WHEREAS:

(A)      Researchers at the University of Cambridge (some of whom were formerly
         in receipt of funding provided by the Lister Institute of Preventive
         Medicine) have developed techniques for performing RNA interference
         ("RNAi") in mammalian cells and embryos which are the subject of an
         international patent application entitled "inhibiting gene expression
         with dsRNA". The research was supported by funding provided by The
         Cancer Research Campaign ("CRC") and Cancer Research UK. The
         researchers and the University have assigned their right, title and
         interest in the foregoing patent application to Cancer Research
         Ventures Limited ("CRV") a wholly owned subsidiary of CRT, and CRV have
         assigned their right, title and interest to CRT.

(B)      CRT is the wholly owned subsidiary of Cancer Research UK and is
         responsible for the management and exploitation of the results derived
         from research funded by CRC and Cancer Research UK. Cancer Research UK
         (registered number 4325234) and registered charity (number 1089464) was
         formed as the successor charity to the Imperial Cancer Research Fund
         and CRC following the merger of their operations with effect from 4
         February 2002.

(C)      Alnylam have requested a licence under the technology described in the
         CRT Patent Rights (as defined below) permitting them to develop
         therapeutics and CRT has agreed to grant a licence to Alnylam on the
         following terms and conditions.

NOW IT IS HEREBY AGREED AS FOLLOWS:

1.       DEFINITIONS AND INTERPRETATION

1.1      In this Licence Agreement and in the Schedules to this Licence
         Agreement the following words and phrases shall have the following
         meanings unless the context requires otherwise:

         "Affiliate"                         means any company, partnership or
                                             other entity which directly or
                                             indirectly Controls, is Controlled
                                             by, or is under common Control
                                             with, any Party including as a
                                             subsidiary or holding company of
                                             any Party.

<PAGE>

                                      - 2 -

         "Blocking IP"                       any and all Patent Rights (other
                                             than that licensed under this
                                             Licence Agreement) which, if claims
                                             covering subject matter of such
                                             Patent Rights issue, would render
                                             the use, development, manufacture,
                                             sale, or other disposal of a
                                             Licensed Product unlawful in the
                                             absence of a licence to such Patent
                                             Rights from a Third Party.

         "Business Day"                      means a day other than a Saturday,
                                             Sunday, bank or other public
                                             holiday in England or the United
                                             States of America.

         "Cancer Research UK-Funded          means any academic researcher in
         Researcher"                         receipt of Cancer Research UK
                                             funding, whether an employee of
                                             Cancer Research UK or a university
                                             employee.

         "Clinical Trial"                    means a clinical trial conducted in
                                             accordance with recognised
                                             protocols approved by a Competent
                                             Authority including CTX clinical
                                             trials or their equivalents
                                             anywhere in the World.

         "Commencement Date"                 means the date first above written.

         "Competent Authority"               means any local or national agency,
                                             authority, department,
                                             inspectorate, minister, ministry
                                             official or public or statutory
                                             person (whether autonomous or not)
                                             of, or of any government of, any
                                             country having jurisdiction over
                                             this Licence Agreement or over any
                                             of the Parties or over the
                                             development or marketing of
                                             medicinal products including, but
                                             not limited to, the European
                                             Commission and the European Court
                                             of Justice.

         "Control"                           means the ownership of at least 50%
                                             of the issued share capital or the
                                             legal power to direct or cause the
                                             direction of the general management
                                             and policies of the Party in
                                             question.

         "CRT Patent Rights"                 means the patent applications
                                             referred to in Schedule 1 and all
                                             Patent Rights deriving priority
                                             from them and all Patent Rights
                                             deriving priority from such Patent
                                             Rights.

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 3 -

         "Field"                             means the development of RNAi
                                             therapeutic products for the
                                             treatment of human disease
                                             (including by means of gene
                                             therapy).

         "Force Majeure"                     means in relation to a Party or its
                                             Affiliate any event or
                                             circumstances which is beyond the
                                             reasonable control of that Party or
                                             its Affiliate which event that
                                             Party or its Affiliate could not
                                             reasonably be expected to have
                                             taken into account at the
                                             Commencement Date and which results
                                             in or causes the failure of that
                                             Party or its Affiliate to perform
                                             any or all of its obligations under
                                             this Licence Agreement including
                                             act of God, lightening, fire,
                                             storm, flood, earthquake,
                                             accumulation of snow or ice, lack
                                             of water arising from weather or
                                             environmental problems, strike,
                                             lockout or other industrial
                                             disturbance, war, terrorist act,
                                             blockade, revolution, riot
                                             insurrection, civil commotion,
                                             public demonstration, sabotage, act
                                             of vandalism, prevention from or
                                             hindrance in obtaining in any way
                                             materials, energy or other
                                             supplies, explosion, fault or
                                             failure of plant or machinery,
                                             governmental restraint, act of
                                             legislature and directive or
                                             requirement of a Competent
                                             Authority governing any Party or
                                             its Affiliate provided that lack of
                                             funds shall not be interpreted as a
                                             cause beyond the reasonable control
                                             of that Party or its Affiliate.

         "Health Registration Approval"      means, with respect to a country in
                                             the Territory, approval by the
                                             health or other Competent Authority
                                             necessary to manufacture and market
                                             a Licensed Product in the country.

         "Issued Valid Claim"                means a claim of an issued and
                                             unexpired and unabandoned patent
                                             included within the CRT Patent
                                             Rights, which claim has not been
                                             held permanently revoked,
                                             unenforceable or invalid by a
                                             decision of a court or other
                                             governmental agency of competent
                                             jurisdiction, unappealable or
                                             unappealed within the time allowed
                                             for appeal, or which has not been
                                             admitted to be invalid or
                                             unenforceable through reissue or
                                             disclaimer or otherwise.

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 4 -

         "Licence Agreement"                 means this agreement and any and
                                             all schedules, appendices and other
                                             addenda to it as may be varied from
                                             time to time in accordance with the
                                             provisions of this agreement.

         "Licensed Products"                 means product or products which, or
                                             the process of production of which,
                                             or the use of which falls within
                                             the scope of a Valid Claim of the
                                             CRT Patent Rights and Licensed
                                             Product shall be construed as any
                                             one of them.

         "Milestone Patent Grant"            means the first grant in the United
                                             States or by the European Patent
                                             Office of a claim comprised within
                                             the CRT Patent Rights, which claim
                                             is substantially similar to and of
                                             equivalent breadth to claim 16 as
                                             originally filed in the PCT
                                             application number [**].

         "Net Sales"                         means the invoiced amount billed
                                             for sales of Royalty Licensed
                                             Products to a Third Party (the
                                             "Customer") by Alnylam or its
                                             Affiliates or by Sub-licensees less
                                             the following items to the extent
                                             they are paid or incurred or
                                             allowed:

                                             a)       quantity, trade and/or
                                                      cash discounts or rebates
                                                      actually granted or
                                                      accrued;

                                             b)       amounts repaid or credited
                                                      and allowances including
                                                      cash, credit or free goods
                                                      allowances, given by
                                                      reason of billing errors
                                                      and rebates actually
                                                      allowed or paid or
                                                      accrued;

                                             c)       amounts refunded or
                                                      credited for Licensed
                                                      Products which were
                                                      rejected or damaged or
                                                      recalled;

                                             d)       taxes, tariffs, customs
                                                      duties and surcharges and
                                                      other governmental charges
                                                      incurred in connection
                                                      with the sale, exportation
                                                      or importation of Licensed
                                                      Products; and

                                             e)       outbound transportation
                                                      costs prepaid or allowed
                                                      and costs of insurance in
                                                      transit.

                                             Where Royalty Licensed Products are
                                             not sold separately, but are sold
                                             together with other therapeutic
                                             agents and such combination has
                                             received regulatory approval,
                                             hereinafter such combinations
                                             referred to as a "Combination
                                             Product" and the Royalty Licensed
                                             Product and each such other product
                                             being referred to as a "Component
                                             Product", the Net Sales price to be
                                             used for the purpose of calculating
                                             royalties payable in respect of
                                             Combination Products shall be
                                             determined by multiplying the Net
                                             Sales price of the Combination
                                             Product by the percentage value of
                                             the Royalty Licensed

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 5 -

                                             Product comprising a Component
                                             Product contained in the
                                             Combination Product and subtracting
                                             the items listed in subsections a)
                                             through e) above, using the
                                             following formula:

                                             A/B = C
                                             C*B = D

                                             "A" equals the selling price of the
                                             Royalty Licensed Product; "B"
                                             equals the selling price of the
                                             Combination Product; "C" represents
                                             the fraction of the selling price
                                             of the Combination Product
                                             attributable to the Royalty
                                             Licensed Product; "D" is the Net
                                             Sales price attributable to the
                                             Royalty Licensed Product to be used
                                             for the purpose of calculating
                                             royalties

                                             If the selling price of a Component
                                             Product is not known the fraction
                                             attributable to the Royalty
                                             Licensed Product shall be
                                             calculated by subtracting the price
                                             sold singly of the other Component
                                             Product from the selling price of
                                             the Combination Product.

                                             If the selling price of each
                                             Component Product is unknown the
                                             Parties agree to negotiate in good
                                             faith to agree on a reasonable
                                             value.

                                             For the sake of consistency the
                                             selling price attributable to the
                                             Royalty Licensed Product shall be
                                             the same whether it is sold singly
                                             or as part of a Combination
                                             Product, providing that the grade,
                                             amount, potency and purity of the
                                             Royalty Licensed Product is the
                                             same when sold singly or in
                                             combination

                                             The transfer of Royalty Licensed
                                             Products by Alnylam or one of its
                                             Affiliates to another Affiliate or
                                             to a Sub-licensee shall not be
                                             considered a sale. In such cases,
                                             Net Sales shall be determined based
                                             on the invoiced sale price levied
                                             by the Affiliate or Sub-licensee on
                                             the Customer, less the
                                             aforementioned deductions to the
                                             extent they are allowed, paid or
                                             accrued.

         "Non-cash Consideration"            means any form of consideration
                                             which is not directly calculable in
                                             monetary terms, including, shares,
                                             goods and cross-licences entered
                                             into by Alnylam.

         "Non-Platform Sub-licence"          means a Sub-licence other than a
                                             Platform Sub-

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 6 -

                                             licence.

         "Non-Platform Sub-licence Income"   means all upfront cash payments
                                             excluding equity and research and
                                             development payments, that accrue
                                             to Alnylam or its Affiliate as of
                                             the commencement date of the
                                             Non-Platform Sub-licence (whether
                                             due on the commencement date of the
                                             Non-Platform Sub-licence or
                                             thereafter) under a Sub-licence
                                             other than a Platform Sub-licence.

         "Parties"                           means CRT and Alnylam and "Party"
                                             shall be construed as either one of
                                             them.

         "Patent Rights"                     means any patent applications,
                                             patents, author certificates,
                                             inventor certificates, utility
                                             models (including all divisions,
                                             renewals, continuations,
                                             continuations-in-part, extensions,
                                             reissues, substitutions,
                                             confirmations, registrations,
                                             revalidations and additions of or
                                             to them, as well as any SPC, or any
                                             like form of protection) and any
                                             foreign counterparts thereto and
                                             patents issuing therefrom.

         "Pivotal Phase II Study"            means a phase II Clinical Trial
                                             upon the basis of which an
                                             application for Health Registration
                                             Approval is made.

         "Platform Sub-licence"              means a bare Sub-licence under the
                                             CRT Patent Rights only and which
                                             grants no rights inter alia: (i) to
                                             Licensed Products developed by
                                             Alnylam or its Affiliate; or (ii)
                                             to develop Licensed Products in
                                             collaboration with Alnylam or its
                                             Affiliate.

         Platform Sub-licence Income         means any and all gross
                                             consideration (including upfront,
                                             periodic, and milestone payments
                                             and Non-cash Consideration) other
                                             than royalty payments on Net Sales
                                             that accrue to Alnylam or its
                                             Affiliates under a Platform
                                             Sub-licence.

         "Quarter"                           means a period of three (3)
                                             consecutive calendar months
                                             commencing on 1 January, 1 April, 1
                                             July or 1 October in any year.

         "Royalty Licensed Product"          means a Licensed Product which, or
                                             the process of production of which,
                                             or the use of which falls within
                                             the scope of an Issued Valid Claim.

                              SECTION CONFIDENTIAL

<PAGE>

                                      - 7-

         "SPC"                               means a right based on a patent
                                             pursuant to which the holder of the
                                             SPC is entitled to exclude third
                                             parties from using, making, having
                                             made, selling or otherwise
                                             disposing or offering to dispose
                                             of, importing or keeping the
                                             product to which the SPC relates,
                                             such as Supplementary Protection
                                             Certificates in Europe, and any
                                             similar right anywhere in the
                                             world.

         "Sub-licence"                       means a sub-licence in the Field
                                             granted by Alnylam or its Affiliate
                                             (in accordance with Clause 2.4).

         "Sub-licensee"                      means any person granted a
                                             Sub-licence by Alnylam or its
                                             Affiliate.

         "Territory"                         means the world.

         "Third Party"                       means any entity or person other
                                             than the Parties or an Affiliate of
                                             a Party.

         "Valid Claim"                       means either:-

                                             a)       a claim of an issued and
                                                      unexpired and unabandoned
                                                      patent included within the
                                                      CRT Patent Rights, which
                                                      claim has not been held
                                                      permanently revoked,
                                                      unenforceable or invalid
                                                      by a decision of a court
                                                      or other governmental
                                                      agency of competent
                                                      jurisdiction, unappealable
                                                      or unappealed within the
                                                      time allowed for appeal,
                                                      or which has not been
                                                      admitted to be invalid or
                                                      unenforceable through
                                                      reissue or disclaimer or
                                                      otherwise; or

                                             b)       a claim of a pending
                                                      patent application
                                                      included within the CRT
                                                      Patent Rights which claim
                                                      was filed in good faith
                                                      and has not been abandoned
                                                      or finally disallowed
                                                      without the possibility of
                                                      appeal or refiling of the
                                                      application.

         "Year"                              means the one (1) year periods
                                             commencing on 31 March annually,
                                             and "Yearly" shall be construed
                                             accordingly.

                              SECTION CONFIDENTIAL

<PAGE>

                                      - 8 -

1.2      In this Licence Agreement:

         1.2.1    unless the context otherwise requires, all references to a
                  particular clause or schedule shall be a reference to that
                  clause or schedule in or to this Licence Agreement as it may
                  be amended from time to time pursuant to this Licence
                  Agreement;

         1.2.2    the headings are inserted for convenience only and shall be
                  ignored in construing this Licence Agreement;

         1.2.3    unless the contrary intention appears, words importing the
                  masculine gender shall include the feminine and vice versa and
                  words in the singular include the plural and vice versa;

         1.2.4    unless the contrary intention appears, words denoting persons
                  shall include any individual, partnership, company,
                  corporation, joint venture, trust association, organisation or
                  other entity, in each case whether or not having separate
                  legal personality;

         1.2.5    the words "include", "included" or "including" are to be
                  construed without limitation to the generality of the
                  preceding words; and

         1.2.6    reference to any statute or regulation includes any
                  modification or re-enactment of that statute or regulation.

2.       GRANT OF LICENCE

2.1      CRT hereby grants to Alnylam, and its Affiliate(s) who have confirmed
         to Alnylam their agreement in writing to be bound (to CRT) by the terms
         of this Licence Agreement which specifically apply to Affiliates, with
         a copy to be sent to CRT, a licence in the Field throughout the
         Territory under the CRT Patent Rights to research, develop, have
         developed, use, keep, make, have made, import, have imported, sell,
         have sold and otherwise dispose or offer to dispose of Licensed
         Products. Such Affiliates shall be listed on Schedule 2 to this Licence
         Agreement which shall be updated periodically by Alnylam and sent to
         CRT. For the sake of clarity, save to the extent necessary for the
         development and/or sale of Licensed Products in the Field neither
         Alnylam or any Affiliate is granted the right to make use of the CRT
         Patent Rights to research, develop, use, keep, make, have made, sell
         and otherwise dispose or offer to dispose of products:

         a)       for any diagnostic application;

         b)       as research tools or reagents;

         c)       for target validation; or

         d)       small molecule drug discovery

         including the provision of services in relation thereto to Affiliates
         or Third Parties.

2.2      Subject to Clause 2.3, the licence granted in Clause 2.1 shall, in
         relation to a particular country in the Territory, be exclusive within
         the Field for the term of the relevant Patent Rights included within
         the CRT Patent Rights.

                              SECTION CONFIDENTIAL

<PAGE>

                                      - 9 -

2.3      It is acknowledged and agreed that CRT and Cancer Research UK shall
         have the right to use, and CRT shall have the right to consent to the
         use by academic research institutions (including for the sake of
         clarity those in receipt of Cancer Research UK funding) of, the CRT
         Patent Rights in the Field for internal, or in collaboration with
         another academic research institution, non-commercial, non-commercially
         sponsored research. For the sake of clarity, Cancer Research UK-funded
         Researchers shall be permitted under the CRT Patent Rights to conduct
         clinical trials of potential dsRNA therapeutic agents as part of their
         Cancer Research UK-funded academic research.

2.4      Alnylam and its Affiliates shall be entitled to sublicence the rights
         granted in this Licence Agreement. Any Sub-licence which is granted in
         breach of this Clause 2.4 shall be void. Alnylam or its Affiliate shall
         (subject to Alnylam's and its Affiliate's right to redact confidential
         information not related to CRT's rights hereunder) provide to CRT in
         confidence a copy of each and every Platform Sub-licence entered into.
         Any Sub-licence entered into by Alnylam or an Affiliate shall;

         a)       be limited to the Field and shall contain restrictions in
                  equivalent terms to those set out in Clause 2.1.

         b)       provide that the Sub-licence shall terminate automatically on
                  the expiry or termination for whatever reason of this Licence
                  Agreement. In the event of termination of this Agreement
                  pursuant to Clause 10, CRT shall enter into a direct licensing
                  arrangement with any Sub-licensee on terms substantially
                  similar to those contained herein save that any licence
                  granted by CRT to any Sub-licensee shall be consistent with
                  the terms of the Sub-licence granted by Alnylam (or its
                  Affiliate as the case may be) in relation to field, territory,
                  exclusivity, rights to sub-license and payment provisions.
                  However, in the event of termination of this Agreement by
                  Alnylam pursuant to Clause 10.2 the provisions of the
                  foregoing sentence shall apply save that the granting of such
                  licence by CRT shall be subject to CRT's consent. Nothing in
                  this Clause 2.4 shall confer upon CRT any obligation to enter
                  into a direct licensing arrangement with the Sub-licensee
                  where the Sub-licensee is in default of its obligations under
                  the Sub-licence. CRT shall not be expected to take any
                  responsibility for any disputes between Alnylam (or its
                  Affiliate as the case may be) and its Sub-licensees relating
                  to the terms of the Sub-licence(s) and notwithstanding the
                  foregoing provisions of this Clause 2.4, CRT shall not be
                  obliged to enter into a direct licence with a Sub-licensee in
                  circumstances in which the Sub-licensee reserves any right to
                  maintain a claim against CRT where such claim was previously
                  maintained against Alnylam (or its Affiliate as the case may
                  be).

         c)       provide that the Third Party with whom the Sub-licence has
                  been entered into shall undertake to CRT directly to allow CRT
                  the same access to the books and records as it has to
                  Alnylam's books and records under this Licence Agreement; and

         d)       contain restrictions on assignment in equivalent terms to
                  those set out in Clause 15 and require that any further
                  sublicensing be subject to the terms of this Clause 2.4.

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 10 -

         Alnylam shall only grant a Platform Sub-licence as a separate licence
         (or sub-licence) for separate consideration identified in the Platform
         Sub-licence and shall not include a Platform Sub-licence as part of any
         other licence (or sub-licence).

2.5      CRT hereby grants an option to Alnylam and its Affiliates exercisable
         during the term of this Licence Agreement to enter into non-exclusive,
         non-sublicensable and non-assignable licences under the CRT Patent
         Rights in the fields of either or both of:

         a)       [**]; and

         b)       [**]

         on terms to be agreed in good faith between CRT and Alnylam, the
         payment terms in respect of each licence which shall be no more than:

         a)       annual payments of [**] pounds sterling ((pound)[**]); or

         b)       any (lesser) sum that may be agreed between CRT and a Third
                  Party licensee after the Commencement Date in the same field
                  (other than a licence pursuant to which, or under the terms of
                  a related agreement, significant resources are provided by the
                  Third Party in respect of a collaboration in the field).

3.       CONSIDERATION

3.1      In consideration of the rights granted under this Licence Agreement,
         Alnylam shall pay the following sums to CRT:

         3.1.1    subject to Clause 3.5, [**] United States dollars (US$[**]) on
                  the Commencement Date; and

         3.1.2    until the expiry of the last to expire of the CRT Patent
                  Rights on each and every anniversary of the Commencement Date,
                  an annual fee of [**] United States dollars (US$[**]); and

         3.1.3    a one-time payment of [**] United States dollars (US$[**]) on
                  Milestone Patent Grant; and

         3.1.4    the following milestone fees in respect of the first Licensed
                  Product in the Field to achieve the milestone (upon
                  achievement of the milestone by Alnylam, or its Affiliate, or
                  a Non-Platform Sub-licensee);

                  (a)      [**] United States dollars (US$[**]) on the
                           commencement of the first phase I Clinical Trial
                           conducted anywhere in the Territory; and

                  (b)      [**] United States dollars (US$[**] on the
                           commencement of the first phase II Clinical Trial or
                           Privotal Phase II Study conducted anywhere in the
                           Territory.

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 11 -

         3.1.5    any and all reasonable patent filing, maintenance and
                  prosecution costs incurred after the Commencement Date by CRT
                  or its agents subject to Clause 7, within 30 (thirty) days of
                  the date of an invoice from CRT.

         3.2      As further consideration of the rights granted under this
                  Licence Agreement, Alnylam (or its Affiliate as the case may
                  be) shall pay the following sums to CRT:

                  3.2.1    royalties of [**] percent ([**]%) of Net Sales of
                           Royalty Licensed Products in the Field; and

                  3.2.2    [**] percent ([**]%) of Platform Sub-licence Income
                           provided that to the extent Platform Sub-licence
                           Income includes;

                           (a)      milestone payment(s) for patent issuance,
                                    the milestone payment made by Alnylam in
                                    Clause 3.1.3 shall be fully creditable
                                    against that part of Platform Sub-licence
                                    Income expressly payable for patent issuance
                                    and Alnylam or its Affiliate shall not pay
                                    [**]% of Platform Sub-licence Income payable
                                    for patent issuance until the milestone
                                    payment made by Alnylam in Clause 3.1.3 has
                                    been fully credited against such Platform
                                    Sub-licence Income; and/or

                           (b)      Non-cash Consideration, Alnylam or its
                                    Affiliate shall following consultation with
                                    CRT have the option of apportioning such
                                    Non-cash Consideration (including by
                                    transfer of [**] percent ([**]%) of
                                    Alnylam's or its Affiliate's shareholding
                                    where Non-Cash Consideration is comprised of
                                    shares), if possible, or valuing the
                                    Non-cash Consideration at its fair market
                                    value, when received and paying [**] percent
                                    ([**]%) of the cash equivalent to CRT; and

                  3.2.3    in respect of each Non-Platform Sub-licence, and
                           solely to the extent that Alnylam or its Affiliate
                           receives Non-Platform Sub-licence Income arising
                           therefrom, [**] percent ([**]%) of Non-Platform
                           Sub-licence Income under such Non-Platform
                           Sub-licence; and

3.3      Provided always that the royalty payable to CRT shall not in any event
         be reduced below [**] percent ([**]%), if at any time prior to or
         during the period for the payment of royalties under this Licence
         Agreement in relation to any particular territory, Alnylam (or its
         Affiliate as the case may be) or a Sub-licensee elects in its
         reasonable opinion to take a licence from a Third Party to any Blocking
         IP to develop, make, sell or otherwise dispose of Licensed Products,
         the royalties set forth in Clause 3.2.1 applicable to such Licensed
         Product shall be reduced by [**]% of the amount paid to such Third
         Party to access said Blocking IP.

3.4      Provided always that Non-Platform Sub-licence Income shall not in any
         event be reduced below [**] percent ([**]%), the percent payment of
         Non-Platform Sub-licence Income set forth in Clause 3.2.3 shall be
         reduced if at any time prior to or

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 12 -

         during the period for the payment thereof under this Licence Agreement
         in relation to any particular territory, in order to grant the rights
         under the Sub-licence Alnylam (or its Affiliate as the case may be)
         elects to take a licence from a Third Party under Patent Rights which
         Alnylam (or its Affiliate as the case may be) reasonably believes to be
         Blocking IP and thereafter the percent of Non-Platform Sub-licence
         Income payable shall be determined by applying the formula [**]N [**]
         where N is the number of Third Party licensors of Blocking IP.

3.5      CRT agrees that in respect of the sum payable under Clause 3.1.1 credit
         shall be given to Alnylam for the sum of [**] dollars (US$[**])
         received by CRT under the terms of a letter of exclusivity dated 4 June
         2003 entered into between the Parties, and provided that Alnylam has
         confirmed that CRT is entitled to retain the said sum, Alnylam shall
         only be obliged to pay [**] dollars (US$[**]) pursuant to Clause 3.1.1.

4.       PAYMENT

4.1      All payments due to CRT under this Licence Agreement shall (subject to
         written advice from CRT amending the account details) be made in United
         States dollars or pounds sterling by telegraphic transfer to the
         accounts below:

         Payee: Cancer Research Technology Limited

         Lloyds TSB, Pall Mall St James's Branch
         8-10 Waterloo Place
         London SW1Y 4BE

         US$ account
         Sort Code: 30-00-08
         Account Code: [**]
         Account Name: Cancer Research Technology Ltd

         Sterling account
         Sort Code: 30-00-08
         Account Code: [**]
         Account Name: Cancer Research Technology Ltd

         For the attention of the Financial Controller (or such other nominee of
         CRT as CRT may direct from time to time).

4.2      Alnylam (or its Affiliate as the case may be) shall make the payments
         to CRT:

         4.2.1    in the case of the royalties payable pursuant to Clause 3.2.1,
                  within 30 (thirty) days of the end of the Quarter in which the
                  sales of the relevant Licensed Products took place;

         4.2.2    in the case of Platform Sub-licence Income and Non-Platform
                  Sub-licence Income payable pursuant to Clauses 3.2.2 and 3.2.3
                  within the later of 30 (thirty) days of the date of receipt of
                  the payment from the Sub-licensee (in respect of any up-front
                  payments) or the end of the Quarter in which the Sub-licence
                  Income has been received by Alnylam;

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 13 -

         4.2.3    in the case of the payments due under Clauses 3.1.1 through
                  3.1.3, within thirty (30) days of the date of an invoice from
                  CRT; and

         4.2.4    in the case of the payments due under Clause 3.1.4, within
                  thirty (30) days of the achievement of the relevant milestone.

4.3      Where sums are received by Alnylam (or its Affiliate as the case may
         be) in a currency other than United States dollars or pounds sterling,
         conversion of such currencies to United States dollars will be
         performed at the closing mid-point rate published in the Financial
         Times in London on the last Business Day of the Quarter in which the
         sum is to be paid. For the sake of clarity Alnylam (or its Affiliate as
         the case may be) shall be under no obligation to convert payments
         received into United States Dollars.

4.4      Where CRT does not receive payment of any sums due to it within thirty
         (30) days of the dates set out in Clauses 3.1 or 4.2 as the case may be
         (the "Due Date"), interest shall accrue on the sum due and owing to CRT
         at the rate equivalent to an annual rate of four percent (4%) over the
         then current US dollar base rate of Lloyds Bank plc, calculated on a
         daily basis, without prejudice to CRT's right to receive payment on the
         Due Date.

4.5      All payments to CRT shall be made free and clear of, and without
         deduction or deferment in respect of, any claims, set-off and taxes
         imposed or levied by any competent authority including any withholding
         taxes. In the event that Alnylam (or its Affiliate as the case may be)
         is obliged to deduct any withholding or other taxes it shall pay to CRT
         an amount as shall result in the net amount being received by CRT being
         equal to the amount which would have been received by CRT had no
         deduction or withholding been made. If CRT is able to recover or
         set-off any such deduction or withholding it shall refund such amount
         to Alnylam (or its Affiliate as the case may be) as shall result in net
         amount being retained by CRT being equal to the amount which would have
         been received by CRT had no deduction or withholding been made. CRT
         shall to any extent reasonably practicable co-operate with Alnylam in
         seeking to effect a recovery from the relevant taxation authority of
         any withholding taxes actually deducted and in the event that CRT makes
         a recovery shall pay to Alnylam (or its Affiliate as the case may be)
         any sums recovered.

5.       BOOKS AND RECORDS

5.1      Following the earlier of the first commercial sale of a Licensed
         Product in the Field by Alnylam or its Affiliate or the grant of a
         Sub-licence, Alnylam (or its Affiliate as the case may be) shall
         prepare an annual statement which shall show on a country by country
         basis for the previous calendar year all monies due to CRT under this
         Licence Agreement. That statement shall include the number of units of
         each Royalty Licensed Product sold in each country in which sales
         occurred, and shall be submitted to CRT within sixty (60) Business Days
         of 31st March of each year. If CRT gives notice to Alnylam within
         twenty (20) Business Days of the receipt of any such statement that it
         does not accept the same, that statement shall be certified by an
         independent accountant appointed by agreement between Alnylam and CRT
         or, in default of agreement within ten (10) Business Days, appointed at
         the request of either

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 14 -

         CRT or Alnylam by the President for the time being of the Institute of
         Chartered Accountants of England and Wales in London. Alnylam (or its
         Affiliate as the case may be) shall make available to the independent
         accountant all books and records required for the purpose of that
         certification under terms of confidentiality equivalent to those
         contained in this Agreement and the statements so certified shall, in
         the absence of manifest error, be final and binding between the
         Parties. The cost of the certification shall be the responsibility of
         Alnylam if the statement is shown to have underestimated the monies
         payable to CRT by more than five percent (5%) and the responsibility of
         CRT otherwise. Any outstanding payments due to CRT which are identified
         as a result of carrying out the investigation shall be paid to CRT
         immediately. There shall be no more than one certification by an
         independent accountant in relation to any one annual statement.

5.2      Alnylam shall, and shall require that its Affiliates and Sub-licensees
         shall, keep true and accurate records and books of account containing
         all data necessary for the calculation of the amounts payable by it to
         CRT pursuant to this Licence Agreement. Such records and books of
         account shall be kept for five (5) years following the end of the
         calendar year to which they relate and shall, upon reasonable notice
         having been given by CRT, be open at all reasonable times on Business
         Days for inspection under the terms of confidentiality contained in
         this Licence Agreement, by an independent firm of accountants appointed
         by agreement between the Parties or, failing such agreement within ten
         (10) Business Days, appointed at the request of either CRT or Alnylam
         by the President for the time being of the Institute of Chartered
         Accountants of England and Wales in London. The cost of any such
         examination shall be borne by CRT, such examination to take place not
         later than five (5) years following the expiration of the period to
         which it relates and there shall be no more than one examination per
         year.

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 15 -

6.       PERFORMANCE AND CLINICAL DEVELOPMENT

6.1      Alnylam shall use reasonable efforts to develop, make, market, sell and
         otherwise dispose of Licensed Products in all therapeutic areas within
         the Field and market each Licensed Product in the Field throughout the
         United States, Europe and Japan. This obligation may be satisfied by
         the efforts of Alnylam's Affiliate(s) or Sub-licensee(s).

6.2      CRT shall provide notice to Alnylam of its knowledge of a willing
         potential sub-licensee. Without prejudice to Clause 6.1, in the event
         that Alnylam (itself or through Affiliates or Sub-licensees) declines
         to develop, make, market, sell or otherwise dispose of Licensed
         Products in any therapeutic area or any indication within the cancer
         therapeutic area within the Field or any territory within the Territory
         in the Field, Alnylam shall (save as hereinafter provided) upon direct
         approach made by, or receipt of notice from CRT of a, willing potential
         sublicensee in respect of a Licensed Product that has demonstrated
         clinical efficacy be obliged to enter into negotiations in good faith
         with such Third Party to enter into a Sub-licence in relation to such
         therapeutic area, indication, or territory. The preceding provisions of
         this Clause 6.2 shall not apply in respect of any therapeutic area,
         indication, or territory in respect of which Alnylam provides to CRT's
         reasonable satisfaction evidence that the conclusion of a Sub-licence
         would:

         6.2.1    be contrary to sound and reasonable business practice
                  applicable to pharmaceutical development; or

         6.2.2    not materially increase the availability of therapeutic
                  products covered by the CRT Patent Rights.

6.3      If CRT believes that Alnylam has failed to meet the diligence
         requirements set forth in Clause 6, it shall serve notice on Alnylam of
         such failure and Alnylam shall have a [**] period from the date of
         receipt of such notice to reestablish diligence towards its objectives,
         and if Alnylam reestablishes diligence towards its objectives during
         this [**] period, any prior lack of diligence will be deemed cured.
         Notwithstanding anything in this agreement to the contrary, in the
         event that Alnylam fails to reestablish diligence to the standard
         provided in Clause 6 within the said [**] period, this shall not be
         cause for CRT's termination of this Licence Agreement, rather, CRT's
         remedy shall be limited to, at CRT's discretion, termination of
         Alnylam's licence under the CRT Patent Rights in the particular
         territory or therapeutic area or, with respect to Clause 6.2,
         indication within the cancer therapeutic area for which Alnylam has
         failed to meet the diligence requirements. For the sake of clarity
         should Alnylam's licence be terminated in respect of a therapeutic area
         or territory pursuant to this Clause 6.3 CRT shall be free to offer
         such therapeutic area or territory to a potential licensee.

         As part of its annual statement deliverable to CRT pursuant to Clause
         6.4, Alnylam shall include a detailed description of therapeutic areas
         and territories under development and an overview of Alnylam's
         development plans for the forthcoming year (itself or through
         Affiliates or Sub-licensees).

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 16 -

6.4      Alnylam shall, within thirty days of the end of each Year provide CRT
         with a written report of the steps taken by Alnylam, its Affiliates and
         any Sub-licensees to comply with the performance obligations of Clauses
         6.1 and 6.2.

6.5      In the event that Alnylam (or its Affiliate as the case may be) intends
         to undertake a Phase I Clinical Trial of any Licensed Product in the UK
         Alnylam shall, at its option (a) notify CRT providing particulars in
         reasonable detail of the proposed investigation; and (b) allow Cancer
         Research UK the opportunity of conducting or procuring the conduct of
         the investigation on behalf of Alnylam or participate in such an
         investigation, subject to the agreement of terms acceptable to Alnylam,
         CRT and Cancer Research UK.

7.       MANAGEMENT OF PATENT RIGHTS

7.1      CRT shall or shall procure in consultation with and (save to the extent
         provided in Clause 7.2) at the reasonable expense of Alnylam the
         filing, prosecution, and maintenance of any patents and patent
         applications comprised within the CRT Patent Rights. CRT shall use
         reasonable efforts to ensure that Alnylam is provided with copies of
         all material correspondence with patent agents in sufficient time for
         Alnylam to comment thereon. Alnylam's comments shall be incorporated to
         the extent reasonably practicable. Alnylam shall (save to the extent
         provided in Clause 7.2) bear the full expense and shall reimburse in
         full and hold CRT harmless in respect of any and all reasonable fees,
         charges, costs, levies or expenses incurred by CRT or its agents after
         the Commencement Date in relation to such applications. Nothing in this
         Licence Agreement shall oblige CRT or Alnylam to bring, defend or
         contest any enforcement, interference, opposition or infringement
         proceedings in respect of any of the CRT Patent Rights.

7.2      Save as hereinafter provided in this Clause 7.2, the reasonable costs
         of opposition and interference proceedings in relation to the CRT
         Patent Rights (together "Challenges") shall be borne equally by the
         Parties. In the event that the total aggregate costs of Challenges in
         any year exceed [**] United States dollars (US$[**]), CRT shall be free
         to make no further contribution to the costs of Challenges and all
         further costs incurred during that year ("Further Challenge Costs")
         and, at Alnylam's option, the future control of such Challenge(s) shall
         be borne by Alnylam solely. CRT shall give credit for [**] percent
         ([**]%) of Further Challenge Costs actually paid by Alnylam against
         sums due from Alnylam to CRT pursuant to Clause 3 from that time
         forward. In the event that one or more of the CRT Patent Rights are the
         subject of a declaration of interference by the U.S. Patent and
         Trademark Office as interfering with claims in a patent or patent
         application which is owned by or licensed by Alnylam or its Affiliate,
         CRT and Alnylam shall negotiate in good faith to reasonably agree on a
         mechanism outside the U.S. Patent and Trademark Office which simplifies
         the issues involved in determining priority and which awards priority
         to the appropriate party to the interference.

         In any country where Alnylam elects not to have a patent application
         included in CRT Patent Rights filed or to pay expenses associated with
         filing, prosecuting, interference or equivalent proceedings, or
         maintaining a patent application or patent included in CRT Patent
         Rights, CRT may file, prosecute, continue with interference or
         equivalent proceedings, and/or maintain such patent application or
         patent at its own expense and

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 17 -

         for its own exclusive benefit and Alnylam (and its Affiliates)
         thereafter shall not be licensed under such patent or patent
         application. For the sake of clarity, should Alnylam elect not to
         continue with interference or equivalent proceedings and CRT elect to
         continue with such proceedings, Alnylam (and its Affiliates) shall
         cease to be licensed for the patent subject to interference for that
         territory.

7.3      If either Party receives any notice, claim or proceedings from any
         Third Party alleging infringement of that Third Party's intellectual
         property by reason of Alnylam's activities in relation to this Licence
         Agreement or the use and exploitation of the CRT Patent Rights by
         Alnylam or its Sub-licensee(s) or its Affiliates, the Party receiving
         that notice shall forthwith notify the other Party of the notice, claim
         or proceeding.

7.4      Alnylam shall, at its option and at its own cost, defend and enforce or
         shall procure the defence or enforcement of the rights under the CRT
         Patent Rights. CRT shall, at Alnylam' reasonable cost, render such
         reasonable assistance as Alnylam reasonably requests. If necessary, CRT
         shall grant to Alnylam the right to conduct such an action in its name.
         Any damages or financial settlement monies received by Alnylam pursuant
         to such proceedings shall, after deduction of all of the costs incurred
         by Alnylam in such proceedings, be treated as Net Sales.

7.5      Without prejudice to CRT's other rights arising from such failure, if
         Alnylam opts not to defend or enforce the relevant CRT Patent Rights
         and if CRT desires to enforce or defend such rights, CRT shall notify
         Alnylam and Alnylam shall, at CRT's request, grant to CRT any and all
         rights that would be necessary for CRT to undertake the enforcement or
         defence. If Alnylam is unable to grant such rights then it shall, at
         CRT's request, grant to CRT the right to conduct such an action in its
         name. Alnylam shall provide, at CRT's request and CRT's reasonable
         expense, such reasonable assistance as CRT may reasonably request in
         any such proceedings. Any monies received by CRT pursuant to any
         enforcement or defence of the CRT Patent Rights by them under this
         Clause 7.5 shall be solely for the benefit of CRT.

8.       WARRANTIES AND LIABILITY

8.1      Each Party represents and warrants to the other Party that it has legal
         power, authority and right to enter into this Licence Agreement and to
         perform its respective obligations hereunder.

8.2      CRT represents and warrants to Alnylam that it has had assigned to it
         all Cambridge University's and the Lister Institute of Preventive
         Medicine's rights under the CRT Patent Rights pursuant to the terms of
         assignments, a copy of which will be provided to Alnylam upon request.

8.3      CRT represents and warrants to Alnylam that to the best of its
         knowledge, upon reasonable inquiry, as at the Commencement Date the
         inventors (as determined by the laws of England) of the patent
         applications referred to in Schedule 1 are [**] and all of these
         inventors have assigned their rights in the CRT Patent Rights to CRV
         (to the extent that the same were not vested in Cambridge University or
         the Lister Institute of Preventive Medicine and assigned to CRT in
         accordance with Clause 8.2). CRV have in turn assigned their rights to
         CRT. In the event of breach of this Clause 8.3,

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 18 -

         Alnylam's remedy for breach shall be limited to the rights conferred
         upon Alnylam by Clause 8.9.

8.4      Other than expressly set out herein, no Party gives any representation
         or warranty to any other Party that the performance of this Licence
         Agreement will not result in the infringement of any rights, including
         intellectual property rights, vested in a Third Party and it is agreed
         and understood by the Parties that Alnylam is responsible for
         undertaking each and every investigation necessary to satisfy itself
         that the rights granted under this Licence Agreement can be properly
         and lawfully exercised by Alnylam (and any Affiliate) without
         infringing the rights of any Third Party, and save as expressly set out
         in Clauses 8.1 and 8.2 no warranties of any kind are given by CRT in
         relation to the intellectual property rights granted under this Licence
         Agreement or owned or controlled by any Third Party which may affect
         the exercise of such rights.

8.5      Nothing in this Licence Agreement shall be construed as a
         representation made or warranty given by CRT in relation to the CRT
         Patent Rights that:

         8.5.1    any patent will issue based upon any pending patent
                  application;

         8.5.2    any patent which issues will be valid; nor

         8.5.3    the use of any CRT Patent Rights will not infringe the patent
                  or proprietary rights of any Third Party.

         Furthermore, CRT makes no representation or warranty, express or
         implied, with respect to merchantability or fitness of the CRT Patent
         Rights for a particular purpose.

8.6      No Party shall be liable to the other Party, its Affiliates or
         Sub-licensees in contract, tort, negligence, breach of statutory duty
         or otherwise for any loss, damage, cost or expense of an indirect or
         consequential nature (including any economic loss or other loss of
         turnover, profits, business or goodwill) arising out of or in
         connection with this Licence Agreement or the subject matter of this
         Licence Agreement.

8.7      Alnylam and any Affiliate licenced under this Licence Agreement shall
         respectively be responsible for and indemnify, defend and hold harmless
         CRT, the University of Cambridge, the Lister Institute of Preventive
         Medicine and their respective officers, servants and agents against any
         and all liability, loss, damage, cost or expense (including reasonable
         attorney's fees and court and other expenses of litigation) arising out
         of or in connection with Third Party claims relating to the discovery,
         research, development, manufacture, marketing, selling and disposal of
         Licensed Products or candidate Licensed Products by Alnylam, its
         Affiliates and their Sub-licensees except to the extent due to the
         gross negligence or wilful misconduct of an indemnitee.

8.8      In the event that CRT intends to seek indemnification under Clause 8.7,
         it shall promptly inform Alnylam (or its Affiliate as the case may be)
         in writing of a claim after receiving notice of the claim and shall
         permit Alnylam (or its Affiliate as the case may be) to direct and
         control the defence of the claim and shall provide such reasonable
         assistance as reasonably requested by Alnylam (or its Affiliate as the
         case may be) (at Alnylam's (or its Affiliate's as the case may be)
         cost) in the defence of

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 19 -

         the claim. Provided always that nothing in this Clause 8.8 shall permit
         Alnylam (or its Affiliate as the case may be) to make any admission on
         behalf of CRT, without the prior written consent of, CRT.

8.9      In the event that a Third Party has rights to the CRT Patent Rights,
         CRT shall obtain, at its cost, such Third Party's rights in the CRT
         Patent Rights to the extent necessary to preserve Alnylam's exclusive
         licence granted under and on the terms of this Licence Agreement. If
         CRT is not able to obtain such rights within one year of learning of
         the existence of such Third Party's rights, Alnylam shall have the
         option to 1) terminate this Licence Agreement; or 2) decrease all
         financial obligations of Alnylam, its Sub-licensees and Affiliates by
         50% in respect of all future revenues, credit 50% of past revenues
         against future revenues owed to CRT under this Licence Agreement and,
         at Alnylam's option, renegotiate the terms of this Licence Agreement
         with CRT in order, to preserve the original intent of this Licence
         Agreement. For the sake of clarity CRT shall not be obliged to repay
         sums received previously.

9.       CONFIDENTIALITY

9.1      Each Party undertakes and agrees not at any time for any reason
         whatsoever to disclose or permit to be disclosed to any Third Party or
         otherwise make use of or permit to be made use of (except as expressly
         permitted by or in conjunction with a licence granted under this
         Licence Agreement), any trade secrets or confidential information
         relating to the other Party's technology or the business affairs or
         finances of the other Party or of an Affiliate, Sub-licensee or of any
         suppliers, agents, distributors or customers of the other Party (the
         "Confidential Information") which come into its possession pursuant to
         this Licence Agreement. Nothing in this Licence Agreement shall prevent
         CRT from disclosing its own information relating to the CRT Patent
         Rights for any purpose outside the Field.

9.2      The Parties shall ensure that only those of their and their Affiliates'
         and Sub-licensee(s) officers, employees, agents and consultants who
         have a need to know are given access to Confidential Information and
         that those who are directly concerned with the carrying out of this
         Licence Agreement and who have access to the Confidential Information
         of the other Party are informed of its secret and confidential nature
         and are bound by obligations of confidentiality and non-use comparable
         to those obligations set forth in this Clause 9.

9.3      The obligations of confidence referred to in this Clause 9 shall not
         extend to any Confidential Information which:

         9.3.1    is at the time of disclosure, or thereafter becomes, available
                  to the public otherwise than by reason of a breach by the
                  recipient Party of the provisions of this Clause 9; or

         9.3.2    is known to the recipient Party without obligations of
                  confidence to the disclosing Party prior to its receipt from
                  the disclosing Party, as can be shown by written record; or

         9.3.3    is subsequently disclosed to the recipient Party by another
                  party owing no obligations of confidentiality to the
                  disclosing Party in respect thereof; or

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 20 -

         9.3.4    is required to be disclosed by any applicable law or any
                  Competent Authority to which a Party is from time to time
                  subject provided to any extent practicable that the disclosing
                  Party receives prior written notice of such disclosure and
                  that the receiving Party takes all reasonable and lawful
                  actions to obtain confidential treatment for such disclosure
                  and, if possible, to minimize the extent of such disclosure;
                  or

         9.3.5    is independently developed by a servant, agent, consultant or
                  employee of the recipient Party having no access to the
                  Confidential Information disclosed by a Party, as demonstrated
                  by written records.

9.4      The obligations of each Party under this Clause 9 shall survive the
         expiration or termination for whatever reason of this Licence Agreement
         for a period of five (5) years.

10.      TERM AND TERMINATION

10.1     This Licence Agreement shall become effective as of the Commencement
         Date and expires when Alnylam's and its Affiliate's obligations to pay
         sums according to Clause 3 finally expire.

10.2     In the event that Alnylam serves a written notice upon CRT confirming
         Alnylam's intention to terminate this Licence Agreement, this Licence
         Agreement shall terminate 90 (ninety) days after receipt by CRT of such
         notice.

10.3     Either CRT on the one hand or Alnylam on the other hand ("the
         Terminating Party") shall have the right to terminate this Licence
         Agreement forthwith upon giving written notice of termination to
         Alnylam on the one hand or CRT on the other hand as the case may be
         ("the Defaulting Party"), upon the occurrence of any of the following
         events at any time during this Licence Agreement:

         10.3.1   the Defaulting Party commits a material breach of this Licence
                  Agreement which in the case of a breach capable of remedy
                  shall not have been remedied within sixty (60) Business Days
                  of the receipt by it of a notice identifying the breach and
                  requiring its remedy;

         10.3.2   the Defaulting Party for a period of longer than sixty (60)
                  Business Days becomes bankrupt or insolvent (including without
                  limitation being deemed to be unable to pay its debts);

         10.3.3   proceedings are commenced in relation to the Defaulting Party
                  under any law, regulation or procedure relating to the
                  re-construction or re-adjustment of debts (including where a
                  petition is filed or proceeding commenced seeking any
                  reorganisation, arrangement, composition or re-adjustment
                  under any applicable bankruptcy, insolvency, moratorium,
                  reorganisation or other similar law affecting creditors'
                  rights or where the Defaulting Party consents to, or
                  acquiesces in, the filing of such a petition), which is not
                  dismissed within ninety (90) days;

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 21 -

         10.3.4   the Defaulting Party takes, any action, or any legal
                  proceedings are started or other steps taken by a Third Party,
                  which proceedings are not dismissed within ninety (90) days
                  with a view to:

                  (i)      the winding up or dissolution of the Defaulting Party
                           (other than for the reconstruction of a solvent
                           company for any purpose, including the inclusion of
                           any part of the share capital of the Defaulting Party
                           on a recognised public Stock Exchange); or

                  (ii)     the appointment of a liquidator, trustee, receiver,
                           administrative receiver, receiver and manager,
                           interim receiver custodian, sequestrator or similar
                           officer of the Defaulting Party against the
                           Defaulting Party or a substantial part of the assets
                           of the Defaulting Party,

                  or anything analogous to any of the foregoing occurs under the
                  laws of any country.

10.4     In the event of Alnylam's material breach of its obligations under
         either or both of Clauses 6.1 and 6.2 CRT shall have the right in its
         absolute discretion to selectively terminate the licence granted under
         Clause 2 in respect of either or both of:

         10.4.1   any therapeutic area or areas within the Field; and

         10.4.2   any territory or territories within the Territory

         in respect of which Alnylam is in material breach as set forth in
         Clause 6.3. In the event of termination by CRT of any part of the
         licence granted to Alnylam under Clause 2 pursuant to the exercise of
         CRT of its rights under this Clause 10.4, the other terms of this
         Licence Agreement (including any surviving licence under Clause 2)
         shall remain in full force and effect.

10.5     CRT shall have the right to terminate this Licence Agreement forthwith
         upon giving thirty (30) days written notice of termination to Alnylam
         in the event that Alnylam or its Affiliate:

         10.5.1   commences legal proceedings, with for the sake of clarity the
                  exception of interference proceedings declared by the USPTO or
                  any other patent office, contesting the validity of the CRT
                  Patent Rights ; or

         10.5.2   commences itself, or provides any material assistance to a
                  Third Party in relation to, legal proceedings contesting the
                  ownership of the CRT Patent Rights.

         For the sake of clarity and notwithstanding anything in this Licence
         Agreement to the contrary, any actions taken concerning determination
         of priority of invention under US patent law between a CRT Patent Right
         and claims in a patent or patent application which is owned by or
         licensed by Alnylam or its Affiliate, shall not be considered a contest
         of validity or ownership under this Clause 10.5.

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 22 -

11.      CONSEQUENCES OF TERMINATION

11.1     Upon termination of this Licence Agreement:

         11.1.1   the licence rights granted by CRT to Alnylam and its
                  Affiliates pursuant to Clause 2 shall terminate in its
                  entirety;

         11.1.2   Alnylam and any Affiliates shall pay to CRT within sixty (60)
                  Business Days all sums due to CRT hereunder which have accrued
                  prior to the date of termination;

         11.1.3   Save that each Party shall be entitled to retain a single copy
                  of any document for their records, Alnylam and CRT shall
                  return to each other any Confidential Information provided
                  under this Agreement.

11.2     Termination or expiry of this Licence Agreement for whatever reason
         shall not affect the accrued rights of the Parties arising in any way
         out of this Licence Agreement as at the date of termination or expiry
         and in particular but without limitation the right to recover damages
         and interest, and the provisions of Clauses 5, 8, 9 and 20 shall remain
         in full force and effect.

12.      WAIVER

12.1     Neither Party or its Affiliate shall be deemed to have waived any of
         its rights or remedies conferred by this Licence Agreement unless the
         waiver is made in writing and signed by a duly authorised
         representative of that Party or its Affiliate. In particular, no delay
         or failure of either Party or its Affiliate in exercising or enforcing
         any of its rights or remedies conferred by this Licence Agreement shall
         operate as a waiver of those rights or remedies or so as to preclude or
         impair the exercise or enforcement of those rights or remedies nor
         shall any partial exercise or enforcement of any right or remedy by
         either Party or its Affiliate preclude or impair any other exercise or
         enforcement of that right or remedy by that Party or its Affiliate.

13.      ENTIRE AGREEMENT/VARIATIONS

13.1     This Licence Agreement constitutes the entire agreement and
         understanding between the Parties and supersedes all prior oral or
         written understandings, arrangements, representations or agreements
         between them relating to the subject matter of this Licence Agreement.
         No director, employee or agent of either Party is authorised to make
         any representation or warranty to another Party not contained in this
         Licence Agreement, and each Party acknowledges that it has not relied
         on any such oral or written representations or warranties.

13.2     No variation, amendments, modification or supplement to this Licence
         Agreement shall be valid unless made in writing in the English language
         and signed by a duly authorised representative of each Party.

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 23 -

14.      NOTICES

14.1     Any notice to be given pursuant to this Licence Agreement shall be in
         writing in the English language and shall be delivered by hand, sent by
         reputable courier service, or sent by facsimile confirmed to the
         address or facsimile number of the recipient set out below or such
         other address or facsimile number as a Party may from time to time
         designate by written notice to the other Party.

         ADDRESS OF CRT

         Sardinia House
         Sardinia Street
         London
         WC2A 3NL

         For the attention of the Chief Executive

         Fax No. ++ 44 207 269 3641

         For the attention of the Chief Executive.

         ADDRESS OF ALNYLAM

         790 Memorial Drive
         Suite 202
         Cambridge, Massachusetts 02139
         United States of America

         For the attention of the Chief Executive
         Fax No. ++1 617 252 0011

14.2     Any notice given pursuant to this Clause 14 shall be deemed to have
         been given upon receipt.

15.      ASSIGNMENT

15.1     Subject to Clause 15.2, neither Party shall without the prior written
         consent of the other Party, which shall not be unreasonably withheld,
         assign the benefit and/or burden of this Licence Agreement nor
         sub-contract any of its obligations hereunder unless otherwise
         permitted by the terms hereof.

15.2     Either Party shall be entitled to assign the benefit and/or burden of
         this Licence Agreement to any Affiliate or to its successor in
         connection with any merger, consolidation or sale or other disposal of
         all or substantially all of its assets and/or business to which this
         Agreement relates.

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 24 -

16.      FORCE MAJEURE

16.1     If a Party or its Affiliate (the "Non-Performing Party") is unable to
         carry out any of its obligations under this Licence Agreement due to
         Force Majeure this Licence Agreement shall remain in effect but the
         Non-Performing Party's relevant obligations under this Licence
         Agreement and the relevant obligations of the other Party ("the
         Innocent Party") under this Licence Agreement shall be suspended for a
         period equal to the duration of the circumstance of Force Majeure
         provided that:

         16.1.1   the suspension of performance is of no greater scope than is
                  required by the Force Majeure;

         16.1.2   the Non-Performing Party gives the Innocent Party prompt
                  notice describing the circumstance of Force Majeure, including
                  the nature of the occurrence and its expected duration, and
                  continues to furnish regular reports during the period of
                  Force Majeure;

         16.1.3   the Non-Performing Party uses all reasonable efforts to remedy
                  its inability to perform and to mitigate the effects of the
                  circumstance of Force Majeure; and

         16.1.4   as soon as practicable after the event which constitutes Force
                  Majeure, the Non-Performing Party shall discuss with the
                  Innocent Party how best to continue its operations as far as
                  possible in accordance with this Licence Agreement.

16.2     If an event of Force Majeure should persist for more than 12 (twelve)
         months in any territory or therapeutic area, and a Third Party has the
         ability and desire to perform Alnylam's or its Affiliate's obligations
         under this Licence Agreement in such territory or therapeutic area, and
         Alnylam or its Affiliate does not enter into good faith negotiations
         with such Third Party during such twelve month period to conclude a
         Sub-licence in such territory or therapeutic area during Alnylam's or
         its Affiliate's period of disability and does not conclude a
         Sub-licence within 18 (eighteen) months of the commencement of the
         event of Force Majeure, then CRT shall have the right to terminate this
         Licence Agreement for such therapeutic area or territory as the case
         may be upon thirty (30) days written notice to Alnylam. The ability and
         desire of a Third Party to enter into a Sub-licence and perform
         Alnylam's or its Affiliate's obligations under this Licence Agreement
         in such territory or therapeutic area shall be demonstrated by CRT
         introducing a potential Sub-licensee who has confirmed in writing the
         terms upon which they agree to be bound. If Alnylam or its Affiliate is
         unable to conclude a Sub-licence with such Third Party, but such Third
         Party agrees nonetheless with CRT on the terms of an agreement to
         perform Alnylam's or its Affiliate's obligations in such territory or
         therapeutic area, then Alnylam or its Affiliate shall be given the
         opportunity to grant a Subl-icence to such Third Party on the same
         terms as those agreed between CRT and such Third Party and uponentering
         a Sub-licence with such Third Party, Alnylam's and its Affiliate's
         rights and obligations under this Licence Agreement in such territory
         or therapeutic area will be reinstated.

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 25 -

17.      SEVERANCE OF TERMS

17.1     If the whole or any part of this Licence Agreement is or becomes or is
         declared illegal, invalid or unenforceable in any jurisdiction for any
         reason (including both by reason of the provisions of any legislation
         and also by reason of any court or Competent Authority which either has
         jurisdiction over this Licence Agreement or has jurisdiction over
         either or both of the Parties):

         17.1.1   in the case of the illegality, invalidity or un-enforceability
                  of the whole of this Licence Agreement it shall terminate only
                  in relation to the jurisdiction in question; or

         17.1.2   in the case of the illegality, invalidity or un-enforceability
                  of part of this Licence Agreement, that part shall be severed
                  from this Licence Agreement in the jurisdiction in question
                  and that illegality, invalidity or un-enforceability shall not
                  in any way whatsoever prejudice or affect the remaining parts
                  of this Licence Agreement which shall continue in full force
                  and effect.

17.2     If in the reasonable opinion of either Party any severance under this
         Clause 17 materially affects the commercial basis of this Licence
         Agreement, the Parties shall negotiate, in good faith, to modify the
         Licence Agreement to eliminate the material effect and to preserve (to
         the extent possible) the original intent. If the parties fail to reach
         a modified agreement within thirty (30) days after the severance under
         this Clause 17, then the dispute shall be resolved in accordance with
         the procedures set forth in Clause 20.

18.      THIS LICENCE AGREEMENT NOT TO CONSTITUTE A PARTNERSHIP

18.1     None of the provisions of this Licence Agreement shall be deemed to
         constitute a partnership between the Parties and no Party shall have
         any authority to bind any other Party in any way except as provided in
         this Licence Agreement.

19.      PUBLIC STATEMENTS

19.1     Except as provided in Clause 19.2, neither Party shall, without the
         prior written consent of the other Parties, which shall not be
         unreasonably withheld:

         19.1.1   use in advertising, publicly or otherwise, any trade-name,
                  personal name, trademark, trade device, service mark, symbol,
                  or any abbreviation, contraction or simulation thereof, owned
                  by another Party (including for the sake of clarity in
                  relation to CRT, Cancer Research UK); or

         19.1.2   represent, either directly or indirectly, that any product or
                  service of another Party is a product or service of the
                  representing Party or that it is made in accordance with or
                  utilises the information or documents of another Party.

19.2     The restrictions in Clause 19.1 shall not apply to the following:

         19.2.1   a press release, in a form agreed to in writing by the
                  Parties, publicly announcing this Licence Agreement; or

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 26 -

         19.2.2   use as required by any applicable law or governmental
                  regulation; or

         19.2.3   a statement that Alnylam or its Affiliate is licensed by CRT
                  under one or more of the patents and/or patent applications
                  comprising the CRT Patent Rights; or

         19.2.4   re-use of any previously agreed to public statement.

20.      GOVERNING LAW AND JURISDICTION

20.1     Save to the extent provided in Clause 20.2, the Parties shall attempt
         to settle any dispute or claim arising out of or relating to this
         Agreement by good faith negotiations. If the Parties fail to agree on a
         reasonable settlement within sixty (60) days after the affected Party
         informed the other Party in writing of such dispute or claim, either
         Party may initiate arbitration under the procedural Rules of the
         American Arbitration Association upon written notice to the other Party
         within thirty (30) days after such failure. The arbitration tribunal
         shall be appointed as follows: each Party shall select, within thirty
         (30) days after notice to initiate arbitration, an independent and
         experienced Third Party as its arbitrator. The two arbitrators selected
         by the parties shall mutually select an independent and experienced
         Third Party as a third arbitrator. The venue for the arbitration
         procedure shall be in London, England and the validity, construction
         and performance of this Licence Agreement shall be governed by the laws
         of England. The award of the arbitration tribunal shall be final and
         binding for the parties. Notwithstanding the foregoing, each Party may
         apply for interlocutory relief in court.

20.2     In the event of a dispute between the Parties as to whether:

         20.2.1   the Milestone Patent Grant has been achieved; or

         20.2.1   Alnylam's belief that any Patent Rights are Blocking IP is
                  reasonable,

         the dispute shall be referred to an independent expert in the field of
         patents (acting as an expert and not as an arbitrator) appointed by
         agreement between the Parties and in the absence of such agreement
         within thirty (30) Business Days, then at the request of either Party
         by the President for the time being of the Chartered Institute of
         Patent Agents. The cost of the expert shall be borne equally by the
         Parties.

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 27 -

                                   SCHEDULE 1

CRT Patent Rights

<TABLE>
<S>           <C>        <C>           <C>       <C>             <C>
[**]          [**]       [**]          [**]      [**]            Pending
------------------------------------------------------------------------
[**]          [**]       [**]          [**]      [**]            Pending
------------------------------------------------------------------------
[**]          [**]       [**]          [**]      [**]            Pending
------------------------------------------------------------------------
[**]          [**]       [**]          [**]      [**]            Pending
------------------------------------------------------------------------
[**]          [**]       [**]          [**]      [**]            Pending
------------------------------------------------------------------------
[**]          [**]       [**]          [**]      [**]            Pending
------------------------------------------------------------------------
[**]          [**]       [**]          [**]      [**]            Pending
------------------------------------------------------------------------
[**]          [**]       [**]          [**]      [**]            Pending
------------------------------------------------------------------------
[**]          [**]       [**]          [**]      [**]            Pending
------------------------------------------------------------------------
[**]          [**]       [**]          [**]      [**]            Pending
------------------------------------------------------------------------
[**]          [**]       [**]          [**]      [**]            Pending
------------------------------------------------------------------------
[**]          [**]       [**]          [**]      [**]            Pending
------------------------------------------------------------------------
[**]          [**]       [**]          [**]      [**]            Pending
------------------------------------------------------------------------
[**]          [**]
------------------------------------------------------------------------
[**]          [**]       [**]          [**]      [**]            Pending
------------------------------------------------------------------------
</TABLE>

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 28 -

                                   SCHEDULE 2

LICENSED AFFILIATES

(details to be provided by Alnylam pursuant to Clause 2.1).

                              SECTION CONFIDENTIAL

<PAGE>

                                     - 29 -

IN WITNESS whereof this Licence Agreement has been executed by duly authorised
officers of the Parties on the date first above written.

Signed by:                 /s/Harpal S. Kumar
                           ---------------------------

Name:                      Harpal S. Kumar

Title:                     Chief Executive
                           For and on behalf of
                           CANCER RESEARCH TECHNOLOGY LIMITED

Signed by:                 /s/John Maraganore
                           ---------------------------

Name:                      John Maraganore

Title:                     CEO
                           For and on behalf of
                           ALNYLAM PHARMACEUTICALS INC

                              SECTION CONFIDENTIAL

<PAGE>

ALNYLAM
   PHARMA

                                              790 MEMORIAL DRIVE - SUITE 220
                                                         CAMBRIDGE, MA 02139
                                                    TELEPHONE - 617-252-0700
                                                            FAX-617-252-0011

5 August 2003

Dr. Robert Kreutzer
Chief Executive Officer
Ribopharma AG
Fritz-Hormschuch-Strasse 9
95326 Kulmbach
Germany

RE:      CANCER RESEARCH TECHNOLOGY LIMITED AND ALNYLAM PHARMACEUTICALS, INC.
         LICENSE AGREEMENT DATED 18 JULY 2003

Dear Roland:

By signing this letter Riopharma AG hereby agrees to be bound to Cancer
Research Technology Ltd. By the terms of the above referenced License Agreement
that specifically apply to Affiliates.

Sincerely,

/s/John G. Conley
John G. Conley
Vice President Strategy, Chief Financial Officer

Acknowledge and Agreed,

/s/Roland Kreutzer                                    August 11, 2003
------------------
Roland Kreutzer

<PAGE>

ALNYLAM
   PHARMA

                                               790 MEMORIAL DRIVE - SUITE 220
                                                          CAMBRIDGE, MA 02139
                                                     TELEPHONE - 617-252-0700
                                                             FAX-617-252-0011

August 27, 2003

                                   VIA COURIER

Harpala S. Kumar
Chief Executive
Cancer Research Technology Ltd.
Sardina House
Sardina Street
London WC2A 3NL
United Kingdom

RE:      AMENDED SCHEDULE 2 TO THE LICENSE AGREEMENT BETWEEN CANCER RESEARCH
         TECHNOLOGY LIMITED AND ALNYLAM PHARMACEUTICALS, INC. DATED 18 JULY 2003

Dear Mr. Kumar

Enclosed please find an Amended Schedule 2 to be attached to our mutual License
Agreement. The amendment adds Ribopharma AG as a licensed Affiliate, now that
our merger has been completed. Pursuant to Clause 2, I have enclosed a copy of a
letter in which Ribopharma AG agrees to be bound as an Affiliate (to CRT) by the
terms of the License Agreement.

Please sign all copies of this letter acknowledging the above and return two
letters to me.

Sincerely,

/s/John M. Maraganore                              Acknowledged and agreed,
John M. Maraganore, Ph.D.
President and Chief Executive Officer
Tel: 617-252-0700                                    /s/Harpal S. Kumar
Fax: 617-252-0011                                    ------------------
jmaraganore@aknylam.com                              Harpal S. Kumar

cc: J.Solbe                                          29/8/03
    R.Kreutzer                                       Date

Enclosures (3)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]